Abstract | BACKGROUND: OBJECTIVE: To evaluate the clinical response and side effects of patients to infliximab. METHODS: A retrospective review of data regarding 18 pediatric and adolescent patients with active CD (n = 15) and UC (n = 3) poorly controlled with conventional therapy. All patients received one to six intravenous infusions of infliximab 5 mg/kg, while receiving their usual medications. RESULTS: CONCLUSIONS: Treatment of our patients with refractory CD and UC with infliximab was associated with remarkable clinical improvement. Although the drug may have an important role in their management, further assessment of long-term safety and efficacy is needed.
|
Authors | M S Serrano, E Schmidt-Sommerfeld, T J Kilbaugh, R F Brown, J N Udall Jr, E E Mannick |
Journal | The Annals of pharmacotherapy
(Ann Pharmacother)
2001 Jul-Aug
Vol. 35
Issue 7-8
Pg. 823-8
ISSN: 1060-0280 [Print] United States |
PMID | 11485127
(Publication Type: Journal Article)
|
Chemical References |
- Antibodies, Monoclonal
- Gastrointestinal Agents
- Infliximab
|
Topics |
- Adolescent
- Adult
- Antibodies, Monoclonal
(administration & dosage, adverse effects, therapeutic use)
- Child
- Colitis, Ulcerative
(drug therapy)
- Crohn Disease
(drug therapy)
- Female
- Gastrointestinal Agents
(administration & dosage, adverse effects, therapeutic use)
- Humans
- Infliximab
- Infusions, Intravenous
- Male
- Recurrence
- Retrospective Studies
- Treatment Outcome
|